Charles Bouchard

Dr. Charles Bouchard


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in The Ocular Surface
Verified
Journal Article
Closed access
CBCharles Bouchard
Charles Bouchard
TJThomas John
Thomas John

24 July 2020 in The Ocular Surface
Verified
Journal Article
Closed access
MZMichael J. Zilliox
Michael J. Zilliox
WGWilliam S. Gange
William S. Gange
GKGina Kuffel
Gina Kuffel
CMCarine R. Mores
Carine R. Mores
CJCara Joyce
Cara Joyce
CBCharles Bouchard
Charles Bouchard

1 December 2012 in Cornea
Verified
Journal Article
Closed access
MHMaylon Hsu
Maylon Hsu
AJAnupam Jayaram
Anupam Jayaram
RVRuth Bs Verner
Ruth Bs Verner
ALAmy Lin
Amy Lin
CBCharles Bouchard
Charles Bouchard
Purpose: To evaluate the indications and outcomes of amniotic membrane transplantation (AMT) performed within the first 2 weeks of presentation in the management of patients with acute Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Methods: A retrospective chart review from January 1998 to May 2011 identified 128 SJS/TEN patients admitted to Loyola University Medical Center Burn intensive care unit. The degree of initial ocular surface inflammation was graded as mild, moderate, or severe within the first 2 weeks of admission. Patients were managed either medically or with amniotic membrane (AM). Outcomes were graded as good [best-corrected visual acuity (BCVA) >20/40], fair (BCVA 20/40 to 20/200 or with ocular surface discomfort, requiring contact lens or reconstructive surgeries), or poor (BCVA <20/200). Results: Of the 182 eyes (91 patients) with documented inpatient eye examinations, 108 eyes (59.4%) had mild or no initial ocular involvement, 37 eyes (20.3%) had moderate, and 37 eyes (20.3%) had severe inflammation. Of the 29 patients (58 eyes) with greater than 1 month of follow-up, 17 patients (33 eyes) were treated with medical management and 13 patients (25 eyes) were treated with early AM. One of the 23 eyes with moderate or severe presentation treated with early AMT (4.3%) resulted in a poor outcome within 3 months compared with 8 of 23 eyes (34.8%) that were medically managed (P = 0.022). Conclusions: We present the first case–control study of the use of AM in the management of acute SJS/TEN. Early use of AMT prevents severe vision loss in SJS/TEN patients with initial moderate or severe ocular surface inflammation.

22 May 2020 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
HLHui Liu
Hui Liu
FGFrank Gambino
Frank Gambino
CACrystal S. Algenio
Crystal S. Algenio
CWCharles Wu
Charles Wu
YGYichen Gao
Yichen Gao
SZShaozhen Zhao
Shaozhen Zhao

1 October 2019 in The Ocular Surface
Verified
Journal Article
Closed access
YGYan Gao
Yan Gao
CLChunhui Li
Chunhui Li
PBPing Bu
Ping Bu
LZLijuan Zhang
Lijuan Zhang
CBCharles Bouchard
Charles Bouchard

1 July 2018 in The Ocular Surface
Verified
Journal Article
Closed access
MSMackenzie Sward
Mackenzie Sward
CKClayton Kirk
Clayton Kirk
SKSunita Kumar
Sunita Kumar
NNNabila Nasir
Nabila Nasir
WAWilliam Adams
William Adams
CBCharles Bouchard
Charles Bouchard